Zentalis Pharmaceuticals: Hanging On For One Last Shot At PROC Approval [Seeking Alpha]
Zentalis Pharmaceuticals (NASDAQ:ZNTL) was upgraded by analysts at
Wall
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target lowered by analysts at Morgan Stanley from $8.00 to $4.00. They now have an "equal weight" rating on the stock.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its "market perform" rating reaffirmed by analysts at Leerink Partners.